Cryoprecipitate transfusion delivers cryoprecipitate, a blood product prepared by slowly thawing frozen plasma, collecting the cold-insoluble precipitate that forms, and refreezing it for storage, to a patient in need of the clotting factors it concentrates. Cryoprecipitate carries fibrinogen, Factor VIII, Factor XIII and von Willebrand factor, and although clotting factor concentrates have replaced it in many clinical contexts where they are available, whole cryoprecipitate is still routinely stocked by many hospital blood banks. Compatibility cross-matching is not required before a cryoprecipitate transfusion, though the product should preferably be ABO compatible with the recipient's red blood cells to avoid the rare complications that can follow a large-volume ABO-incompatible transfusion.
Facts
Connections
Sources
1. Wikipedia: Cryoprecipitate
WikipediaSection on cryoprecipitate history, sentence naming Judith Graham Pool and 1964
While the current method for producing cryoprecipitate was developed by Judith Graham Pool from Stanford University in 1964, it was initially approved in 1971 by the U.S. Food and Drug Administration under the name Cryoprecipitated AHF for the Hoxworth Blood Center University of Cincinnati Medical Center.
- Clinical use status
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.
View At A Past Year
Choose a year to see this entry's facts and connections as the atlas records them at that moment: what it held then, what it held instead, and what it had not yet adopted. Choose Present for the current record.